FCS Welcomes Drs. Fishman & Teklie

Florida Cancer Specialists & Research Institute (FCS) has added hematologists/oncologists Troy Fishman, MD and Yeshanew Teklie, MD to its team. Dr. Fishman will practice in Pinellas County, while Dr. Teklie will serve patients in The Villages and surrounding areas. Both bring extensive experience and a commitment to patient-centered care.

Florida Cancer Specialists & Research Institute (FCS) announced the expansion of its physician network with the addition of two new specialists. Dr. Troy Fishman and Dr. Yeshanew Teklie join the team, bringing additional expertise in hematology and medical oncology to FCS‘s growing practice.

Dr. Fishman, who will see patients at the FCS Mease clinic in Clearwater, Florida, completed his medical education at St. George’s University School of Medicine and subsequent training at the University of Central Florida and Roger Williams Medical Center. FCS leadership highlighted Dr. Fishman‘s dedication to individualized patient care and creating personalized treatment plans.

Meanwhile, Dr. Teklie will serve patients at multiple FCS locations in The Villages, Florida and surrounding areas. His background includes medical training at Ross University School of Medicine, residency at Florida State University in conjunction with Sarasota Memorial Hospital, and a fellowship at the University of Southern California LAC+USC Medical Center. FCS emphasized Dr. Teklie‘s specialized knowledge of hematologic cancers and his commitment to community care.

The additions of Drs. Fishman and Teklie reflect FCS‘s ongoing commitment to expanding access to high-quality cancer care throughout Florida. The organization operates numerous clinics across the state, offering a wide array of services and participating in numerous clinical trials.

FCS has a long history of involvement in cancer research, providing patients access to cutting-edge treatments and contributing significantly to the advancement of oncology. The organization’s commitment to research has placed it at the forefront of private oncology practices in the state and nationally. Many new cancer drugs receive initial patient access through FCS‘s clinical trials before gaining full FDA approval. This commitment to innovation and patient care is a cornerstone of FCS‘s mission.

Share: X Facebook LinkedIn WhatsApp
Share your love